Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Masahiro Gotoh
Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11
Oncotarget
Oncology
Identification of Human Cadherin-14, a Novel Neurally Specific Type II Cadherin, by Protein Interaction Cloning
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Related publications
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Oncologist
Cancer Research
Medicine
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
S‐1 Plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
Oncologist
Cancer Research
Medicine
Oncology
A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
Clinical Colorectal Cancer
Oncology
Gastroenterology
"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study
BMC Cancer
Cancer Research
Oncology
Genetics
A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
